BRPI0517075A - uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer - Google Patents

uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer

Info

Publication number
BRPI0517075A
BRPI0517075A BRPI0517075-3A BRPI0517075A BRPI0517075A BR PI0517075 A BRPI0517075 A BR PI0517075A BR PI0517075 A BRPI0517075 A BR PI0517075A BR PI0517075 A BRPI0517075 A BR PI0517075A
Authority
BR
Brazil
Prior art keywords
kinase inhibitor
growth factor
factor receptor
cancer treatment
receptor kinase
Prior art date
Application number
BRPI0517075-3A
Other languages
English (en)
Inventor
Paul M Harari
Prakash Chinnaiyan
Shymin Jason Huang
Original Assignee
Paul M Harari
Prakash Chinnaiyan
Shymin Jason Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul M Harari, Prakash Chinnaiyan, Shymin Jason Huang filed Critical Paul M Harari
Publication of BRPI0517075A publication Critical patent/BRPI0517075A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE UM INIBIDOR DE CINASE DE RECEPTOR DE FATOR DE CRESCIMENTO EPIDéRMICO E RADIAçãO DE IONIZAçãO PARA TRATAMENTO DE CáNCER. A presente invenção fornece um método para a fabricação de um medicamento destinado ao tratamento de tumores ou metástases de tumor em um paciente, caracterizado pelo fato de que uma quantidade terapeuticamente eficaz de um inibidor de cinase de EGFR e radiação de ionização é usada, sem ou com agentes ou tratamentos adicionais, tais como outras drogas anticâncer. Um exemplo preferido de um inibidor de cinase de EGFR que pode ser usado na prática desta invenção é o composto HCI de erlotinib (também conhecido como Tarceva(r)).
BRPI0517075-3A 2004-10-18 2005-10-18 uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer BRPI0517075A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61970504P 2004-10-18 2004-10-18
PCT/US2005/037325 WO2006110176A2 (en) 2004-10-18 2005-10-18 Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor

Publications (1)

Publication Number Publication Date
BRPI0517075A true BRPI0517075A (pt) 2008-09-30

Family

ID=37067547

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517075-3A BRPI0517075A (pt) 2004-10-18 2005-10-18 uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer

Country Status (11)

Country Link
US (2) US20060084666A1 (pt)
EP (1) EP1804837A2 (pt)
JP (1) JP2008516984A (pt)
KR (1) KR20070083720A (pt)
CN (1) CN101043905A (pt)
AU (1) AU2005330508A1 (pt)
BR (1) BRPI0517075A (pt)
CA (1) CA2584075A1 (pt)
IL (1) IL182525A0 (pt)
MX (1) MX2007004633A (pt)
WO (1) WO2006110176A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006146625A (ru) * 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение иринотеканом (срт-11) и ингибитором рецептора эпидермального фактора роста (egfr)
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
EA017864B1 (ru) * 2007-01-18 2013-03-29 Мерк Патент Гмбх Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
WO2010129515A1 (en) * 2009-05-08 2010-11-11 The United Satates Of America As Represented By The Secretary, Department Of Health & Human Services Modulation of the tgf-beta and pi3k/akt pathways in the diagnosis and treatment of squamous cell carcinoma
WO2012099968A1 (en) * 2011-01-19 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating skin cancer associated diseases
WO2013048345A1 (en) * 2011-09-28 2013-04-04 Agency For Science, Technology And Research Methods and pharmaceutical compositions for treating cancer
KR101579054B1 (ko) * 2014-03-26 2015-12-21 한국원자력의학원 포도필로톡신 아세테이트를 유효 성분으로 포함하는 방사선치료 증진제
US9937179B2 (en) 2014-04-04 2018-04-10 Crown Bioscience Uk Ltd Combined treatment for cancer resistant to an epidermal growth factor receptor kinase inhibitor
JP2018517462A (ja) 2015-05-05 2018-07-05 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 個人化された放射線療法を得るためのシステム及び方法
KR101875111B1 (ko) * 2016-04-29 2018-07-09 한국수력원자력 주식회사 저선량 방사선을 이용한 암화유전자 Ras-유도 악성 암화 억제
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
KR102763598B1 (ko) * 2022-05-18 2025-02-07 한국원자력의학원 포도필로톡신 유도체를 유효성분으로 포함하는 방사선 치료 증진제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200100603A (et) * 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
CA2436326C (en) * 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
CA2482591A1 (en) * 2002-04-16 2003-10-30 Astrazeneca Ab Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
AU2005330508A1 (en) 2006-10-19
WO2006110176A2 (en) 2006-10-19
CA2584075A1 (en) 2006-10-19
US20090253721A1 (en) 2009-10-08
IL182525A0 (en) 2007-09-20
CN101043905A (zh) 2007-09-26
MX2007004633A (es) 2007-10-11
KR20070083720A (ko) 2007-08-24
WO2006110176A3 (en) 2007-01-25
JP2008516984A (ja) 2008-05-22
EP1804837A2 (en) 2007-07-11
US20060084666A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
WO2007106503A3 (en) Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
WO2019197605A3 (en) Drug combinations for use in the treatment of ras-mutant cancer
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
ZA201907225B (en) Treatment of her2 positive cancers
BRPI0622054B8 (pt) composto e composição farmacêutica
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
BRPI0413066A (pt) derivado de quinazolina, ou um sal farmaceuticamente aceitável, ou um éster farmaceuticamente aceitável do mesmo, da fórmula i, uso e processo para a preparação do mesmo, composto, composição farmacêutica, e, métodos para a produção de um efeito antiproliferativo em um animal de sangue quente, para a prevenção ou tratamento de um tumor, para prover um efeito inibitório de tirosina quinase de egfr seletivo, e para tratar um cáncer em um animal de sangue quente
EA200500893A1 (ru) Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2023000577A (es) Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa.
WO2006110176A3 (en) Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
BR0207443A (pt) Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
BR112023014247A2 (pt) Composições farmacêuticas para tratar cânceres de mama e métodos de usos destas
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
DE60311788D1 (de) Kombinationstherapie zur behandlung von krebs
BR112022026386A2 (pt) Inibidor de fgfr e mutação, método de preparação do mesmo e uso farmacêutico do mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.